Survodutide

It was just guidance towards regulatory rulemaking, but it wasn't actually putting down regulations necessarily.

yet but regardless potentially transformative for the us peptide compounding industry so we'll we'll pay attention more to see what's going on there in the not too distant future hopefully number five we have Servodutide and Pemvedutide.

Again, I hope I didn't butcher those.

But these peptides, these two are especially for liver disease and addiction, showing that metabolic peptides are becoming disease platform drugs.

First, how does this investigational drug actually work? Think of standard GLP-1s as a single-engine plane.

Servodutide is a dual agonist.

It basically adds a second engine by also targeting glucagon receptors to boost energy burn.

To test this twin-engine approach, researchers ran a 76-week trial with 725 adults who had obesity but no diabetes.